Remission of cold-agglutinin autoimmune hemolytic anemia and hypereosinophilic syndrome with rituximab therapy

J Allergy Clin Immunol Pract. 2021 May;9(5):2107-2108.e4. doi: 10.1016/j.jaip.2020.12.066. Epub 2021 Jan 18.

Authors

Lauren Wetzler¹, Sandhya Panch², Alexis Berry¹, Amy D Klion¹, Paneez Khoury³

Affiliations

¹ Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Md.
² Department of Transfusion Medicine, National Institutes of Health, Bethesda, Md.
³ Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Md. Electronic address: khouryp@nih.gov.

PMID: 33476787
DOI: 10.1016/j.jaip.2020.12.066

No abstract available

Publication types

Research Support, N.I.H., Intramural

MeSH terms

Agglutinins
Anemia, Hemolytic, Autoimmune* / diagnosis
Anemia, Hemolytic, Autoimmune* / drug therapy
Antibodies, Monoclonal
Humans
Hypereosinophilic Syndrome* / diagnosis
Hypereosinophilic Syndrome* / drug therapy
Rituximab / therapeutic use

Substances

Agglutinins
Antibodies, Monoclonal
Rituximab